In prostate cancer, OC inhibits dihydrotestosterone (DHT)-induced ERα/AR cross-talk, reducing PSA expression by 80% in LNCaP cells via the dual blockade of ERK1/2 and AKT phosphorylation [132]. Here, AR is linked to prostate carcinoma.